Review: antidepressants plus benzodiazepines lead to fewer drop outs and less depression severity in major depression


QUESTION: In adults with major depression, does combination treatment with antidepressants and benzodiazepines lead to short term (< 8 wk) or long term (> 2 mo) symptomatic recovery or side effects?

Data sources
Studies were identified by searching Medline, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts, Biological Abstracts, LILACS, PsycLIT, the Cochrane Library, and the trial register of the Cochrane Depression, Anxiety, and Neurosis Group (January 1972 to December 1998); hand searching major mental health and general medicine journals; scanning the reference lists of identified articles; checking SciSearch; and making personal contacts.

Study selection
Studies were selected if they were randomised controlled trials comparing combined antidepressant-benzodiazepine treatment with antidepressants alone in adults with major depression. Studies were excluded if the antidepressant dose was < 100 mg of imipramine, or its equivalent daily, or the duration of the trial was < 4 weeks.

Main results
9 studies (679 patients) met the selection criteria. The antidepressants studied were imipramine, desipramine, amitriptyline, maprotiline, nortriptyline, clomipramine, fluoxetine, and mianserin; benzodiazepines studied included triazolam, alprazolam, diazepam, clorazepoxide, flunitrazepam, lorazepam, benzepam, clonazepam, and mexitazolam. Patients allocated to the combined treatment group were less likely to drop out of the study than those in the antidepressant alone group (table). Patients in the combined treatment group were also less likely to drop out because of side effects (table). More patients in the combined treatment group showed a > 50% reduction from their baseline depression severity at 4 weeks than did those in the antidepressant alone group (worst case scenario for drop outs; table). This difference was no longer statistically significant at 8 weeks.

Conclusion
In adults with major depression, a combination of antidepressant and benzodiazepine treatment leads to fewer drop outs and less depression severity at 4 weeks than do antidepressants alone.

Combined antidepressant and benzodiazepine treatment v antidepressants alone for major depression*

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Weighted event rates</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dropped out</td>
<td>22%</td>
<td>37% (19 to 51)</td>
<td>10 (6 to 22)</td>
</tr>
<tr>
<td>Dropped out because of side effects</td>
<td>7%</td>
<td>48% (14 to 68)</td>
<td>15 (10 to 40)</td>
</tr>
<tr>
<td>&gt;50% reduction in depression at 4 weeks</td>
<td></td>
<td>38% (15 to 66)</td>
<td>7 (5 to 15)</td>
</tr>
</tbody>
</table>

*Abbreviations defined in glossary; RRR, RBI, NNT, and CI calculated from data in article.

Harm Gijsman, MD
University of Oxford, Oxford, UK

Review: antidepressants plus benzodiazepines lead to fewer drop outs and less depression severity in major depression

Evid Based Med 2001 6: 184
doi: 10.1136/ebm.6.6.184

Updated information and services can be found at:
http://ebm.bmj.com/content/6/6/184

These include:

References
This article cites 2 articles, 0 of which you can access for free at:
http://ebm.bmj.com/content/6/6/184#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: musculoskeletal and joint diseases (349)
Mood disorders (including depression) (97)
Clinical trials (epidemiology) (1596)
Drugs: CNS (not psychiatric) (262)
Health policy (216)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/